NCT00768209CompletedPhase 1
A Phase I, Open Label, Single-Dose Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment and In Healthy Control Subjects
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- VIVUS LLC
- Enrollment
- 18
- Locations
- 2
- Primary Endpoint
- Pharmacokinetics
Study Overview
Brief Summary
This study is designed to determine the effects of a single dose of the study medication in subjects with and without hepatic impairment. 18 to 24 subjects will participate by having multiple blood draws taken to measure the level of study medication in their blood over time.
Detailed Description
This study will look at the effect of a single does of study medication in three groups. Each group will have 6 - 8 subjects with similar levels of hepatic impairment. Group 1 will have normal hepatic function. Groups 2 and 3 will be made up of subjects with mild to moderate hepatic impairment. Subjects will have blood taken at specific intervals to measure study medication levels. Subject participation will last approximately 7 to 9 days.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •A total of 18 to 24 subjects will be studied in 3 groups of 6-8 subjects per group. Group 1 will consist of 6-8 males or females with normal hepatic function, 18 to 65 years of age inclusive. Groups 2-3 will consist of 6-8 males or females per group with varying degree of stable hepatic impairment.
Exclusion Criteria
- •Any Subject meeting the following criteria must be excluded from the trial:
- •Known history of clinically significant arrhythmias.
- •Acute illness, especially any infection, within 2 weeks of dosing.
- •History or presence of:
- •Alcoholism or drug abuse within the past 2 years.
- •Hypersensitivity or idiosyncratic reaction to compounds related to the study drug or related compounds.
- •Any History of Bipolar disorder or psychosis, history of psychiatric hospitalization, greater than one lifetime episode of major depression.
- •Blood donation or significant blood loss within 56 days prior to Day
- •Plasma donation within 7 days prior to Day
- •Any subject who has participated in a previous clinical trial with VI-
- •Any subject who received an investigational drug within 30 days prior to dosing in this study.
- •Any history of glaucoma, increased intraocular pressure, or medications to treat increased intraocular pressure.
- •Serum creatinine > 1.5 for male subjects, and >1.4 for female subjects.
- •History of kidney stones in the last 6 months
- •Female subjects, who may be pregnant, or are lactating.
- •Use of any drug that is known to have clinical significance in inhibiting or inducing liver enzymes involved in drug metabolism.
- •Use of tobacco or nicotine products within last 6 months unless subject is hepatically-impaired.
Arms & Interventions
Treatment A
Experimental
Intervention: Phentermine and Topiramate (Drug)
Outcomes
Primary Outcomes
Pharmacokinetics
Time Frame: 9 days
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic FunctionHepatic ImpairmentNCT01631097AVEO Pharmaceuticals, Inc.44
Completed
Phase 1
The Effect of Reduced Liver Function on Selatogrel PharmacokineticsHealthy SubjectsHepatic ImpairmentNCT04406896Viatris Innovation GmbH24
Completed
Phase 1
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy ParticipantsHepatic InsufficiencyNCT03341884Genentech, Inc.29
Active, not recruiting
Phase 1
A study to evaluate how inavolisib is processed in the body of participants with moderate and highly reduced kidney functioISRCTN11899726F. Hoffmann-La Roche Ltd32
Completed
Phase 1
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese SubjectsInfection, Human Immunodeficiency VirusNCT01332565ViiV Healthcare10